Zoetis Releases Update of M. Hyo Manual

DURHAM, N.C., September 30, 2020 — Zoetis has released an update of the comprehensive manual, “A Contemporary Review of Mycoplasma Hyopneumoniae Control Strategies,” a 62-page booklet with 14 articles developed by swine-disease experts specializing in this pathogen.

The revised booklet features an updated section on breeding-herd classifications and an entirely new section on fogging for controlled exposure to Mycoplasma hyopneumoniae (M. hyo).

Also known as enzootic pneumonia, mycoplasma pneumonia is a prevalent and costly disease caused by Mycoplasma hyopneumoniae (M. hyo). In damaging the cilia (tiny hairs lining pigs’ upper respiratory airways), the disease exposes the respiratory tract to bacterial and viral infections and coinfections by other pathogens.

“Respiratory infection caused by M. hyo has been a well-known feature of swine production for decades,” said Lucina Galina Pantoja, DVM, PhD, director, U.S. Pork Technical Services, Zoetis. “Despite a long acquaintance with M. hyo and its principal clinical manifestation, enzootic pneumonia (EP), some gaps in our understanding of the disease and its control still remain, and new information on diagnosis and management of M. hyo infection has emerged.” 

“The purpose of this review is to provide a comprehensive update on M. hyo,” she added.

The manual is structured as a five-step approach for managing M. hyo in the production setting, including:

  • Establishing herd status classification criteria for breeding herds 
  • Diagnosis of infection 
  • Risk management 
  • Control measures 
  • Monitoring intervention strategies

"Regardless of a farm’s M. hyo status, there are chapters in this manual that will be beneficial for production veterinarians,” Galina noted.

To download a copy of the updated M. hyo manual, visit www.pighealthtoday.com.

About Zoetis 
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees. For more information, visit https://www.zoetisus.com.

For further information, contact
Julie Groce 
Zoetis US LLC 

Ronda Pick 
PR Works 



Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2022 Zoetis Services LLC. All rights reserved.